A federal jury in Chicago has ordered the pharmaceutical company AbbVie Inc. to pay a Tennessee man more than $140 million as compensation for a heart attack he claimed was caused by his taking the testosterone-replacement drug AndroGel.
The Oct. 5 verdict, first reported by Reuters, was delivered after a mistrial was declared in June when one of plaintiff Jeffrey Konrad’s lead attorneys became ill.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
